Index NDX, S&P 500
P/E 26.38
EPS (ttm) 8.01
Insider Own 0.77%
Shs Outstand 144.90M
Perf Week -6.73%
Market Cap 30.75B
Forward P/E 12.21
EPS next Y 17.30
Insider Trans -0.09%
Shs Float 144.48M
Perf Month -5.92%
Income 1.17B
PEG 6.68
EPS next Q 4.01
Inst Own 89.51%
Short Float 2.51%
Perf Quarter 4.30%
Sales 9.29B
P/S 3.31
EPS this Y 5.96%
Inst Trans 0.82%
Short Ratio 3.52
Perf Half Y -14.23%
Book/sh 104.48
P/B 2.02
EPS next Y 10.90%
ROA 4.56%
Short Interest 3.63M
Perf Year -20.39%
Cash/sh 7.38
P/C 28.62
EPS next 5Y 3.95%
ROE 8.04%
52W Range 189.44 - 278.95
Perf YTD -18.39%
Dividend Est. -
P/FCF -
EPS past 5Y -18.05%
ROI 5.32%
52W High -24.30%
Beta -0.04
Dividend TTM -
Quick Ratio 1.32
Sales past 5Y -4.53%
Gross Margin 68.31%
52W Low 11.47%
ATR (14) 7.26
Dividend Ex-Date -
Current Ratio 2.10
EPS Y/Y TTM -62.75%
Oper. Margin 18.67%
RSI (14) 35.17
Volatility 2.92% 2.96%
Employees 7570
Debt/Eq 0.46
Sales Y/Y TTM -2.49%
Profit Margin 12.56%
Recom 1.67
Target Price 280.90
Option/Short Yes / Yes
LT Debt/Eq 0.44
EPS Q/Q 0.93%
Payout 0.00%
Rel Volume 2.14
Prev Close 227.44
Sales Surprise -0.80%
EPS Surprise 5.78%
Sales Q/Q -5.62%
Earnings Aug 01 BMO
Avg Volume 1.03M
Price 211.17
SMA20 -7.36%
SMA50 -7.06%
SMA200 -8.71%
Trades
Volume 2,209,242
Change -7.15%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-14-24 Reiterated
Needham
Buy
$305 → $300
Feb-14-24 Downgrade
Wells Fargo
Overweight → Equal Weight
$315 → $240
Jan-24-24 Downgrade
UBS
Buy → Neutral
$311 → $276
Dec-20-23 Resumed
Cantor Fitzgerald
Overweight
$311
Dec-07-23 Upgrade
Raymond James
Mkt Perform → Outperform
$283
Sep-06-23 Initiated
HSBC Securities
Buy
$360
Jul-27-23 Initiated
Scotiabank
Sector Outperform
$327
Jul-24-23 Reiterated
UBS
Buy
$346 → $335
May-01-23 Upgrade
Guggenheim
Neutral → Buy
$270 → $350
Apr-17-23 Upgrade
Piper Sandler
Neutral → Overweight
$280 → $346
Oct-26-22 Upgrade
Goldman
Neutral → Buy
$220 → $370
Oct-13-22 Upgrade
Stifel
Hold → Buy
$223 → $299
Oct-07-22 Upgrade
Argus
Hold → Buy
$300
Sep-28-22 Upgrade
Robert W. Baird
Neutral → Outperform
$224 → $340
Sep-28-22 Upgrade
Mizuho
Neutral → Buy
$207 → $270
Sep-28-22 Upgrade
BMO Capital Markets
Market Perform → Outperform
$217 → $360
Apr-18-22 Upgrade
Wells Fargo
Equal Weight → Overweight
$235 → $265
Mar-08-22 Downgrade
Stifel
Buy → Hold
$304 → $223
Mar-03-22 Upgrade
RBC Capital Mkts
Sector Perform → Outperform
$227 → $248
Feb-04-22 Reiterated
Wolfe Research
Peer Perform
$244 → $217
Show Previous Ratings
Today 05:12PM
04:15PM
(Investor's Business Daily)
01:14PM
10:48AM
10:21AM
09:48AM
Loading…
09:48AM
(Associated Press Finance)
08:00AM
(Investor's Business Daily)
07:20AM
Jul-25-24 10:02AM
04:52AM
Jul-24-24 04:07PM
(Investor's Business Daily)
10:34AM
09:37AM
08:10AM
06:30AM
03:52AM
Loading…
Jul-23-24 03:52AM
Jul-22-24 04:27PM
(Investor's Business Daily)
08:14AM
01:12AM
Jul-17-24 09:50AM
Jul-16-24 04:02PM
(Investor's Business Daily)
12:45PM
11:55AM
(Investor's Business Daily)
05:10AM
04:00AM
Jul-12-24 08:00AM
(Investor's Business Daily)
Jul-10-24 03:25PM
01:08PM
Jul-09-24 07:51PM
Jul-05-24 06:20AM
12:37PM
Loading…
Jul-03-24 12:37PM
11:14AM
(Pharmaceutical Technology)
11:14AM
08:00AM
(Investor's Business Daily)
07:55AM
Jul-02-24 04:13PM
(Investor's Business Daily)
02:16PM
(Investor's Business Daily)
12:45PM
09:16AM
Jul-01-24 01:00AM
Jun-29-24 08:45PM
Jun-28-24 06:13AM
(Pharmaceutical Technology)
Jun-27-24 09:02PM
07:39PM
02:33PM
(Investor's Business Daily)
Jun-26-24 05:45AM
03:12AM
(Pharmaceutical Technology)
Jun-25-24 08:37AM
Jun-24-24 09:50AM
07:30AM
Jun-20-24 01:38PM
(Investor's Business Daily)
Jun-17-24 07:00AM
(The Wall Street Journal)
01:12AM
Jun-15-24 04:00PM
Jun-14-24 06:45PM
05:45AM
Jun-11-24 04:07PM
(Investor's Business Daily)
12:25PM
12:20PM
(Investor's Business Daily)
08:45AM
08:22AM
07:35AM
Jun-10-24 10:12PM
05:17PM
(Investor's Business Daily)
04:18PM
10:27AM
(Investor's Business Daily)
09:54AM
Jun-09-24 07:37PM
Jun-07-24 02:00PM
(Investor's Business Daily)
11:41AM
Jun-06-24 05:23PM
09:50AM
05:45AM
Jun-03-24 07:30AM
Jun-02-24 07:00AM
May-31-24 12:25PM
11:42AM
10:17AM
08:00AM
(Investor's Business Daily)
04:25AM
(Pharmaceutical Technology)
May-30-24 04:51PM
08:30AM
(Investor's Business Daily)
May-29-24 10:27AM
07:02AM
May-28-24 11:21AM
May-27-24 06:35AM
(Pharmaceutical Technology)
03:02AM
May-25-24 11:15PM
11:10PM
May-24-24 11:31AM
May-23-24 10:06AM
08:54AM
(Pharmaceutical Technology)
May-22-24 07:28PM
09:55AM
08:25AM
07:37AM
07:30AM
07:19AM
May-21-24 09:50AM
May-17-24 06:15AM
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Keeney Adam Head of Corporate Development May 01 '24 Option Exercise 0.00 938 0 938 May 03 08:00 PM Singhal Priya Head of Development Apr 02 '24 Sale 213.09 93 19,817 4,886 Apr 03 08:24 PM Murphy Nicole Head of Pharm Ops and Tech Apr 01 '24 Option Exercise 0.00 240 0 9,751 Apr 03 08:11 PM Singhal Priya Head of Development Feb 22 '24 Sale 221.23 262 57,962 4,886 Feb 26 07:54 PM Singhal Priya Head of Development Feb 16 '24 Option Exercise 0.00 1,208 0 5,429 Feb 21 09:27 PM ALEXANDER SUSAN H EVP Chief Legal Officer Feb 16 '24 Option Exercise 0.00 5,037 0 52,506 Feb 21 09:39 PM Gregory Ginger EVP, Human Resources Feb 16 '24 Option Exercise 0.00 4,704 0 14,341 Feb 21 09:36 PM Izzar Rachid Head of Global Product Strat. Feb 16 '24 Option Exercise 0.00 2,017 0 10,014 Feb 21 09:33 PM Kramer Robin Chief Accounting Officer Feb 16 '24 Option Exercise 0.00 1,345 0 6,354 Feb 21 09:31 PM MCDONNELL MICHAEL R EVP, Chief Financial Officer Feb 16 '24 Option Exercise 0.00 6,720 0 20,692 Feb 21 09:29 PM Murphy Nicole Head of Pharm Ops and Tech Feb 16 '24 Option Exercise 0.00 1,260 0 9,624 Feb 21 09:28 PM Singhal Priya Head of Development Feb 16 '24 Sale 221.49 108 23,921 5,148 Feb 21 09:27 PM Rowinsky Eric K Director Feb 15 '24 Buy 222.54 455 101,256 20,629 Feb 20 09:13 PM Singhal Priya Head of Development Feb 12 '24 Sale 239.45 419 100,330 4,516 Feb 13 06:06 PM Izzar Rachid Head of Global Product Strat. Feb 09 '24 Option Exercise 0.00 1,515 0 9,081 Feb 13 06:00 PM Singhal Priya Head of Development Feb 09 '24 Option Exercise 0.00 1,212 0 5,309 Feb 13 06:06 PM Murphy Nicole Head of Pharm Ops and Tech Feb 09 '24 Option Exercise 0.00 2,272 0 9,529 Feb 13 06:04 PM MCDONNELL MICHAEL R EVP, Chief Financial Officer Feb 09 '24 Option Exercise 0.00 3,257 0 17,555 Feb 13 06:03 PM Kramer Robin Chief Accounting Officer Feb 09 '24 Option Exercise 0.00 833 0 5,523 Feb 13 06:01 PM Gregory Ginger EVP, Human Resources Feb 09 '24 Option Exercise 0.00 2,158 0 11,778 Feb 13 06:14 PM ALEXANDER SUSAN H EVP Chief Legal Officer Feb 09 '24 Option Exercise 0.00 2,575 0 50,021 Feb 13 05:56 PM MCDONNELL MICHAEL R EVP, Chief Financial Officer Feb 08 '24 Option Exercise 0.00 2,335 0 15,063 Feb 09 08:03 PM Murphy Nicole Head of Pharm Ops and Tech Feb 08 '24 Option Exercise 0.00 2,101 0 7,895 Feb 09 08:01 PM Kramer Robin Chief Accounting Officer Feb 08 '24 Option Exercise 0.00 788 0 4,943 Feb 09 08:06 PM Gregory Ginger EVP, Human Resources Feb 08 '24 Option Exercise 0.00 1,635 0 10,118 Feb 09 08:14 PM Izzar Rachid Head of Global Product Strat. Feb 08 '24 Option Exercise 0.00 2,043 0 8,187 Feb 09 08:11 PM ALEXANDER SUSAN H EVP Chief Legal Officer Feb 08 '24 Option Exercise 0.00 2,190 0 48,101 Feb 09 08:16 PM Singhal Priya Head of Development Feb 02 '24 Sale 245.93 634 155,920 4,097 Feb 05 06:38 PM Singhal Priya Head of Development Feb 01 '24 Option Exercise 0.00 1,828 0 5,292 Feb 05 06:38 PM Singhal Priya Head of Development Dec 11 '23 Sale 248.00 110 27,280 3,464 Dec 12 05:06 PM Kramer Robin Chief Accounting Officer Dec 08 '23 Option Exercise 0.00 351 0 4,325 Dec 12 05:02 PM Singhal Priya Head of Development Dec 08 '23 Option Exercise 0.00 426 0 3,780 Dec 12 05:06 PM BIOGEN INC. 10% Owner Sep 26 '23 Sale 0.50 6,000,000 3,000,000 17,652,466 Sep 28 05:30 PM Singhal Priya Head of Development Sep 05 '23 Sale 269.43 431 116,124 3,354 Sep 06 06:06 PM MCDONNELL MICHAEL R EVP, Chief Financial Officer Sep 01 '23 Option Exercise 0.00 5,285 0 14,060 Sep 06 06:08 PM Singhal Priya Head of Development Sep 01 '23 Option Exercise 0.00 1,668 0 4,592 Sep 06 06:06 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite